Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
DNA vaccination wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
Lymphopoiesis wikipedia , lookup
Molecular mimicry wikipedia , lookup
Immune system wikipedia , lookup
Adaptive immune system wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Innate immune system wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Subordination of the neoplastic progression to the immune system Dr Céline Bossard Department of Pathology, University Hospital, Nantes [email protected] Tumor immunity : an old concept with new clinical applications • Ehrlich in 1909 proposed this idea : « tumors are not entirely « self », and immunemediated recognition of autologous tumor cells could be able to eliminate transformed cells » • A concept formalized subsequently by Thomas and Burnett: « the immune surveillance » to refer the recognition and destruction of newly appearing tumor cells which are seen as foreign by the immune system • But the development of cancer implies - an imperfect immune surveillance - mechanisms of tumor immune escape, representing potential new therapeutic targets (ex : anti PD-1, PD-L1 antibodies) Clinical evidences for tumour immunity • Spontaneous regression of melanoma associated with an in situ T cell clonal expansion (Ferradini et al, 1993) • The increased risk of tumour development in immunosuppressed patients (primary or secondary immunodeficiencies) : - tumours of viral origin : > B-cell lymphoma induce by Epstein Barr Virus, > Kaposi’s sarcoma and HHV8, > carcinoma of the anogenital regions and HPV - tumours with no known viral etiology : > melanoma, sarcoma, lung adenocarcinoma…. • The improved prognosis of tumours containing a high number of tumourinfiltrating lymphocytes (TIL: T cells, NK cells) : > melanoma (identification of various melanoma-specific Ag) > colon, breast, ovarian adenocarcinomas, head and neck carcinomas….. The tumor microenvironment contains more or less immune cells • Stroma : a complex microenvironnement composed of : - blood and lymphatic vessels - an inflammatory milieu consisting of immune cells (of the innate and adaptive immunity) and their secretory products type, density and location of immune cells varie between each tumour and influence tumour progression differently In the center, in the stroma In close contact with tumor cells Immune cells at the invasive margin of the tumor Immune cells in close contact with tumour cells (intra-epithelial TIL) The major effector cell in anti-tumor immunity: the Cytotoxic T Lymphocyte (CTL) Cell mediated immunity is the major anti tumor mechanism Prognostic Value of Tumor Infiltrating Lymphocytes in the Vertical Growth Phase of Primary Cutaneous Melanoma Claudio G. Clemente et al, 1996 High number of TIL Low number of TIL Presence of high number of TIL is a positive prognostic factor Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer Lin Zhang et al, 2003, N Eng J Med CD8 immunostaining : intratumoral and peritumoral CD8+ T cells The presence of intratumoral T cells correlated with delayed recurrence or delayed death Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. J Galon et al, 2006 Patients with a homogeneous increased expression of genes for Th1 adaptive immunity (CD3, CD8, GrB, IFNg) in the tumour have a better prognosis. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. J Galon et al, 2006 Center of the tumour The high density of CD3+ TIL is associated with a better prognosis, whatever their localization CD8+ IEL-TIL Bossard et al, 2012 Int J Cancer Invasive margin ….T cells infiltrate has a prognostic discriminatory power that is superior to the standard TNM staging system…. The immune score as a new possible approach for the cancer staging in colorectal carcinomas Galon et al, 2012 J Translational Medicine NK cells : an effector cell of the innate immunity • They may provide the first line of defense agains tumor cells • NK cells can lyse a wide range of human tumors, including some tumors that seem to be nonimmunogenic for T cells - tumours that fail to express MHC class I Ag cannot be recognized by CTL, but by NK cells that destroy cells without normal expression of MHC class I Ag • Some studies have demonstrated the favorable prognostic impact of NK cells infiltration in various type of tumors : - colorectal cancer (Coca et al, Cancer, 1997) - gastric cancer (Ishigami et al, Cancer Lett, 2000) Intra-epithelial CD244+ NK cells in colorectal adenocarcinoma C Bossard, 2012, Int J Cancer Tumor antigens • Classified depending on their molecular structure and source • They can induce or not a specific immune response 1 - Products of mutated oncogenes and tumor suppressor genes • Neoplastic transformation results from genetic alterations, and some of them may lead to the expression of cell surface Ag (with known or unknown function), seen as non-self by the immune system. • Tumor-specific Ag (p53, RAS, BRAF, b-catenin, and many others not related to the transformed phenotype as in MSI tumors….) not expressed by normal cells • Shared by many different tumors • Recognized as non-self proteins by the immune system • These self-mutant proteins can induce specific CTL, but these CTL don’t elicit a protective response • The product of an unmutated oncogene is overexpressed in a subset a breast cancers : HER2/NEU oncogene • Can be assessed by immunohistochemistry and/or FISH • The target of a monoclonal antibody : Trastuzumab (Herceptin) 2 - Overexpressed or aberrantly expressed normal proteins • Structurally normal protein overexpressed in tumor cells = normal self-Ag - ex : tyrosinase in melanoma cell (expressed at a low level only in normal melanocyte) > T cells in patients with melanoma recognize peptides derived from tyrosinase > development of tyrosinase vaccine (clinical trials ongoing) • Cancer-testis antigen: Ag only expressed in testis but without antigenic expression at the cell surface (no MHC class I expression by sperm !), but with deregulated expression in tumor cells > A tumor-specific Ag ex : the MAGE family of genes (Melanoma Antigen Gene); MAGE Ag are found in melanoma, lung, liver, stomach….. > several MAGE Ag are used in tumor vaccine trials Tumor antigen produced by oncogenic viruses • Somes virus are associated with cancers (HPV and cervix, HBV, HCV and hepatocarcinoma, EBV and lymphomas….) • Produced proteins are recognized as foreign and induced a strong CTL response (DNA viruses +++) > vaccines against HPV Ags are effective to prevent cervical cancer +++ Oncofetal/embryonic antigens • Ag only expressed during the embryogenesis but not in normal adult tissues ex : CEA (carcinoembryonic Ag in colon cancer) and α foetoprotein in liver cancer > used as serum markers of cancer Altered cell surface glycolipids or glycoproteins • Most human tumors expressed higher than normal levels and/or altered forms of glycolipids or glycoproteins • Can be used as diagnostic markers and/or targets for therapy • These molecules include gangliosides, mucins, bloog group Ag ex : CA-125, CA 19-9, MUC-1 Cell type-specific differentiation antigens • Differentiation Ag are specific molecules expressed in particular lineages or at a differentiation stage of various cell types = normal self Ag • Tumor cell can express a differentiation Ag normaly expressed by the normal cell counterpart • They do not induce immune response > use for identifying the tissue of origin for a morphologically undifferentiated tumor (IHC) > use as a target for immunotherapy : anti-CD20 antibody (Rituximab) used in B-cell lymphomas expressing CD20 as normal B lymphocytes How do tumor cells escape from the immune system in immunocompetent hosts? The immune evasion by tumor Several escape mechanisms have been proposed T cells Dendritic cell Lymph node MHC TCR Tumor cell Peripheral tissue TCR MHC class I X Activation signal X B7 B7 CD28 Inhibitory signal CTLA-4 TGFb Negative regulation PD-L1 PD-1 PD-L2 ✔ From Ribas A in N Eng J Med, 2012:366;26 Overexpression of HLA-E/β2m by tumour cells in CRC is associated with a high number of inhibitory CD94/NKG2 +IEL-TIL, and with a poor prognosis HLA-E CD94 P=0.02 Tumour cell LYSIS HLA-E/β2m – HLA-E/β2m + Bossard et al, Int J Cancer, 2012 β2M NK cell and CTL Conclusion • Type, density and location of immune cells within a tumour can predict the prognosis in some tumours > proposition of an « immune score » for the classification of cancer • Host immune cells have essential roles in regulating tumour growth in the tumour microenvironment. • Host immune cells provide a great opportunity for therapeutic and preventive interventions > need to boost the effective and specific anti-tumor immune response, and to inhibit the mechanisms of tumor immune evasion